Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Krystal Biotech Price Performance

KRYS traded down $9.76 on Friday, reaching $163.64. 541,492 shares of the company's stock were exchanged, compared to its average volume of 322,730. The stock has a market cap of $4.71 billion, a PE ratio of 92.66 and a beta of 0.80. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34. The stock's fifty day moving average price is $181.54 and its 200-day moving average price is $184.87.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same period in the prior year, the business earned ($0.67) earnings per share. The business's revenue was up 879.9% compared to the same quarter last year. As a group, research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Chardan Capital restated a "buy" rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Thursday. Stifel Nicolaus lifted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Finally, HC Wainwright restated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $202.86.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Blue Trust Inc. grew its holdings in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after purchasing an additional 163 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company's stock valued at $173,000 after buying an additional 94 shares during the period. Louisiana State Employees Retirement System purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at approximately $2,296,000. EFG Asset Management North America Corp. raised its position in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company's stock valued at $2,308,000 after buying an additional 60 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock valued at $35,583,000 after acquiring an additional 103,928 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.